Volume 6, Number 2—April 2000
Research
Serologic Response to Culture Filtrate Antigens of Mycobacterium ulcerans during Buruli Ulcer Disease
Karen M. Dobos*†, Ellen A. Spotts*†, Barbara J. Marston*, C. Robert Horsburgh*, and C. Harold King*
Table 3
Antibody responses to specific Mycobacterium ulcerans culture filtrate proteins in all Buruli ulcer patients and controls
| Clinical Presentation | 5 kDa (%) | 36/38 kDa (%) | 70 kDa (%) | All Three (%) | Any (%)a |
|---|---|---|---|---|---|
| Total BU patients (n= 61) (%) | 14 (22.9) | 31 (50.8) | 37 (60.7) | 8 (13.1) | 43 (70.5) |
| Healed (n = 29) | 8 (27.6) | 15 (51.7) | 17 (58.6) | 7 (24.1) | 20 (69.0) |
| Ulcerative (n = 22) | 6 (27.3) | 10 (45.5) | 14 (63.6) | 2 (9.1) | 16 (72.7) |
| Early ulcerative (n=10) (%) | 0 (0.0) | 6 (60.0) | 6 (60.0) | 0 (0.0) | 7 (70.0) |
| No scar or ulcer (n= 27) (%) | 7 (25.9) | 4 (14.8) | 3 (11.1) | 1 (3.7) | 10 (37.0) |
| U.S. TB patients (n= 13) (%) | 3 (23.1) | 3 (23.1) | 0 (0.0) | 0 (0.0) | 4 (30.8) |
aDenotes total number (percentage) of persons within the population with an antibody response to any one, or a mixture of, the three specified MUCF proteins. MUCF = Mycobacterium ulcerans culture filtrate
Page created: December 16, 2010
Page updated: December 16, 2010
Page reviewed: December 16, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.